Trials / Recruiting
RecruitingNCT07129642
Allogeneic Anti-CD19 CAR-T for Refractory Graves' Disease
The Efficacy and Safety of Allogenic Anti-CD19 CAR-T Cell Therapy for Refractory Graves' Disease
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 5 (estimated)
- Sponsor
- Shanghai Zhongshan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Graves' disease is an autoimmune disease. The TSH receptor antibody(TRab) produced by B cells drives the production of thyroid hormone, which causes systemic disorders and thyroid eye disease. The purpose of this study is to investigate the efficacy and safety of allogeneic anti-CD19 CAR-T for refractory Graves' disease. The participants with refractory Graves' disease will receive a single dose of allogeneic anti-CD19 CAR-T and be regularly seen for the change of serum TRab, FT3, FT4 and clinical presentations, as well as any adverse events.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Allogeneic CAR-T | The participants will receive one dose of allogeneic CAR-T |
Timeline
- Start date
- 2025-08-10
- Primary completion
- 2026-12-31
- Completion
- 2027-03-31
- First posted
- 2025-08-19
- Last updated
- 2025-08-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07129642. Inclusion in this directory is not an endorsement.